Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


gefitinib resistance ( 30 / 16 /
4
/
10
)
gemcitabine resistance ( 52 / 26 /
8
/
18
)
genomic instability ( 4 / 2 /
1
/
1
)
gluconeogenesis ( 4 / 2 /
0
/
2
)
5fluorouracil resistance ( 118 / 68 /
22
/
28
)
adhesion ( 49 / 27 /
7
/
15
)
Adriamycin (Adr) resistance ( 26 / 14 /
3
/
9
)
aerobic glycolysis ( 69 / 35 /
11
/
23
)
Afatinib resistance ( 2 / 1 /
0
/
1
)
AKT signaling ( 279 / 141 /
47
/
91
)
anchorage-independent growth ( 33 / 17 /
10
/
6
)
Angiogenesis ( 282 / 146 /
46
/
90
)
Anoikis ( 22 / 12 /
4
/
6
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Apoptosis ( 1794 / 911 /
574
/
309
)
Autophagy ( 323 / 162 /
73
/
88
)
beta-catenin signaling ( 65 / 33 /
12
/
20
)
BMP signaling ( 108 / 63 /
13
/
32
)
Bone metastasis ( 26 / 15 /
3
/
8
)
BRAFi resistance ( 4 / 2 /
1
/
1
)
Brain metastasis ( 2 / 1 /
0
/
1
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
BRCAness ( 2 / 1 /
1
/
0
)
Camptothecin resistance ( 3 / 2 /
0
/
1
)
cancer progression ( 16 / 9 /
5
/
2
)
carboplatin resistance ( 4 / 2 /
1
/
1
)
Castrate Resistance ( 25 / 15 /
8
/
2
)
cell cycle ( 254 / 133 /
45
/
76
)
cell cycle arrest ( 507 / 257 /
222
/
28
)
cell cycle progression ( 181 / 92 /
43
/
46
)
Cell growth ( 762 / 385 /
114
/
263
)
cell polarity ( 1 / 1 /
0
/
0
)
cell spreading ( 8 / 6 /
0
/
2
)
cell viability ( 296 / 152 /
36
/
108
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
Chemoresistance ( 290 / 146 /
56
/
88
)
colony formation ( 503 / 257 /
65
/
181
)
differentiation ( 95 / 48 /
31
/
16
)
DNA repair ( 59 / 30 /
21
/
8
)
EMT ( 873 / 443 /
183
/
247
)
growth ( 222 / 131 /
26
/
65
)
inflammation ( 79 / 40 /
14
/
25
)
Invasion ( 3533 / 1792 /
564
/
1177
)
MET ( 18 / 10 /
8
/
)
Metastasis ( 1097 / 557 /
216
/
324
)
migration ( 2831 / 1431 /
447
/
953
)
motility ( 201 / 103 /
33
/
65
)
NF-kB signaling ( 169 / 86 /
40
/
43
)
Oxaliplatin ( 2 / 1 /
1
/
)
Oxaliplatin resistance ( 27 / 14 /
6
/
7
)
Paclitaxel resistance ( 67 / 34 /
13
/
20
)
Proliferation ( 4018 / 2029 /
642
/
1347
)
Radioresistance ( 129 / 66 /
25
/
38
)
Senescence ( 69 / 38 /
23
/
8
)
stemness ( 223 / 112 /
52
/
59
)
survival ( 134 / 69 /
23
/
42
)
Tamoxifen resistance ( 19 / 10 /
6
/
3
)
cisplatin resistance ( 316 / 159 /
54
/
103
)
doxorubicin resistance ( 75 / 38 /
10
/
27
)
ERK pathway (MAPK pathway) ( 163 / 82 /
27
/
54
)
etoposide ( 7 / 4 /
2
/
1
)
Liver metastasis ( 28 / 16 /
4
/
8
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
multidrug resistance ( 22 / 12 /
5
/
5
)
RAS signaling pathway ( 8 / 5 /
1
/
2
)
tumor growth ( 770 / 388 /
130
/
252
)
Lung metastasis ( 57 / 30 /
12
/
15
)
PI3K signaling ( 95 / 48 /
16
/
31
)
WNT signaling ( 372 / 187 /
86
/
99
)
Hedgehog (Hh) signaling ( 31 / 16 /
5
/
10
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
tumor-stroma interactions ( 3 / 2 /
1
/
)
docetaxel resistance ( 41 / 22 /
14
/
5
)
epirubicin resistance ( 5 / 3 /
2
/
)
JAK/STAT signaling ( 102 / 52 /
27
/
23
)
mTOR signaling ( 82 / 41 /
8
/
33
)
Necrosis ( 4 / 2 /
1
/
1
)
NOTCH signaling ( 69 / 35 /
17
/
17
)
P38 signaling ( 31 / 16 /
10
/
5
)
poor prognosis ( 46 / 26 /
17
/
3
)
Transformation ( 15 / 12 /
2
/
1
)
tumor progression ( 82 / 42 /
24
/
16
)
Tumorigenesis ( 43 / 22 /
7
/
14
)
Vorinostat Resistance ( 6 / 4 /
2
/
)
cytotoxicity ( 2 / 1 /
1
/
)
TGF-beta signaling ( 376 / 211 /
82
/
83
)
Temozolomide (TMZ) resistance ( 34 / 17 /
6
/
11
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
)
T cell activation ( 3 / 2 /
1
/
)
Sorafenib resistance ( 28 / 14 /
6
/
8
)
glucose metabolism ( 18 / 9 /
3
/
6
)
MEKi resistance ( 4 / 2 /
1
/
1
)
immunoevasion ( 26 / 13 /
7
/
6
)
Hippo signaling pathway ( 168 / 84 /
65
/
19
)
fibrosis ( 30 / 15 /
6
/
9
)
MAPK/JNK Signaling Pathway ( 12 / 6 /
5
/
1
)
Hypoxic response ( 10 / 6 /
4
/
)
Taxanes (paclitaxel and docetaxel) resistance ( 12 / 9 /
2
/
1
)
Trastuzumab resistance ( 8 / 4 /
2
/
2
)
TRAIL resistance ( 14 / 7 /
4
/
3
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)
pyroptosis ( 4 / 2 /
1
/
1
)
tumor-initiating properties ( 9 / 6 /
/
3
)
ER stress ( 28 / 15 /
/
13
)
inflammatory monocyte recruitment ( 4 / 3 /
/
1
)
Imatinib resistance ( 12 / 8 /
/
4
)
NK cell cytotoxicity ( 6 / 4 /
/
2
)
disease-free survival ( 3 / 2 /
/
1
)
MTX resistance ( 3 / 2 /
/
1
)
Osteolysis ( 5 / 3 /
/
2
)
unfolded protein response ( 5 / 4 /
/
1
)
lipogenesis ( 23 / 12 /
/
11
)
Lapatinib resistance ( 2 / 1 /
/
1
)
Neratinib resistance ( 2 / 1 /
/
1
)
Rapamycin resistance ( 2 / 1 /
/
1
)
BCL2 inhibitors resistance ( 2 / 1 /
/
1
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
erythropoiesis ( 3 / 3 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Response to oxidative stress ( 8 / 8 /
0
/
0
)
Response to genotoxic stress ( 2 / 2 /
0
/
0
)
scattering ( 1 / 1 /
0
/
0
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)
chondrogenesis ( 1 / 1 /
0
/
0
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
EGFR-TKI resistance ( 2 / 2 /
0
/
0
)
glycolysis ( 11 / 11 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
macrophage attraction ( 1 / 1 /
0
/
0
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)